187
Views
2
CrossRef citations to date
0
Altmetric
Assessment Procedures

Validity, reliability and responsiveness to change of the French version of the drooling impact scale

ORCID Icon, , ORCID Icon, , ORCID Icon, ORCID Icon, & ORCID Icon show all
Pages 788-794 | Received 17 Oct 2019, Accepted 30 May 2020, Published online: 17 Jun 2020

References

  • Meningaud JP, Pitak-Arnnop P, Chikhani L, et al. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(1):48–57.
  • Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012;(11):CD008624.
  • Cans C. Epidémiologie de la Paralysie Cérébrale («Cerebral Palsy» ou CP). Mot Cérébrale. 2005;26(2):51e8.
  • Chaléat-Valayer E, Porte M, Buchet-Poyau K, et al. Management of drooling in children with cerebral palsy: a French survey. Eur J Paediatr Neurol. 2016;20(4):524–531.
  • Van der Burg JJ, Jongerius PH, Van Hulst K, et al. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev Med Child Neurol. 2006;48(2):103–107.
  • Senner JE, Logemann J, Zecker S, et al. Drooling, saliva production, and swallowing in cerebral palsy. Dev Med Child Neurol. 2004;46(12):801–816.
  • Jongerius PH, van Tiel P, van Limbeek J, et al. A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child. 2003;88(10):911–914.
  • Porte M, Chaléat-Valayer E, Patte K, et al. Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: a review. Eur J Paediatr Neurol. 2014;18(6):649–649657.
  • Rodwell K, Edwards P, Ware R, et al. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review. Dev Med Child Neurol. 2012;54(11):977e87–977987.
  • Hughes A, Choi S. Does intraglandular injection of botulinum toxin improve pediatric sialorrhea? Laryngoscope. 2018;128(7):1513–1514.
  • Pena AH, Cahill AM, Gonzalez L, et al. Botulinum toxin A injection of salivary glands in children with drooling and chronic aspiration. J Vasc Interv Radiol. 2009;20(3):368–373.
  • Bothwell JE, Clarke K, Dooley JM, et al. Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol. 2002;27(1):18e22–18e22.
  • Lin YC, Shieh JY, Cheng ML, Yang PY. Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy. Neurology. 2008;70(4):316–31318.
  • Jongerius PH, van den Hoogen FJ, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics. 2004;114(3):620–62627.
  • Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res. 2000;79(11):1874–1878.
  • Meece RW, Fishlock KF, Bayley EW, et al. Ultrasound- guided botox injections of salivary glands in children with drooling. J Radiol Nurs. 2010;29(1):20e4–2024.
  • Hegde AM, Pani SC. Drooling of saliva in children with cerebral palsy-etiology, prevalence, and relationship to salivary flow rate in an indian population. Spec Care Dentist. 2009;29(4):163–16168.
  • Reid SM, Johnstone BR, Westbury C, et al. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol. 2008;50(2):123e8–12128.
  • Reid SM, Johnson HM, Reddihough DS. The drooling impact scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol. 2010;52(2):e23e8–e2e28.
  • Beaton DE, Bombardier C, Guillemin F, et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–3191.
  • De Vet HC, Terwee CB, Mokkink LB, et al. Measurement in medicine: a practical guide. New York: Cambridge University Press; 2011.
  • Blasco PA. Management of drooling: 10 years after the Consortium on Drooling, 1990. Dev Med Child Neurol. 2007;44(11):778–781.
  • Parr JR, Todhunter E, Pennington L, et al. Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child. 2018;103(4):371–376.
  • Russo EF, Calabrò RS, Sale P, et al. Can muscle vibration be the future in the treatment of cerebral palsy-related drooling? A feasibility study. Int J Med Sci. 2019;16(11):1447–1452.
  • Reid SM, Westbury C, Guzys AT, et al. Anticholinergic medications for reducing drooling in children with developmental disability. Dev Med Child Neurol. 2020;62(3):346–353.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.